Authors: Takamatsu, N Kim, ON Welage, LS Idkaidek, NM Hayashi, Y Barnett, J Yamamoto, R Lipka, E Lennernas, H Hussain, A Lesko, L Amidon, GL

Citation: N. Takamatsu et al., Human jejunal permeability of two polar drugs: Cimetidine and ranitidine, PHARM RES, 18(6), 2001, pp. 742-744

Authors: Hilgendorf, C Spahn-Langguth, H Regardh, CG Lipka, E Amidon, GL Langguth, P

Citation: C. Hilgendorf et al., Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport, J PHARM SCI, 89(1), 2000, pp. 63-75

Authors: Smaill, JB Rewcastle, GW Loo, JA Greis, KD Chan, OH Reyner, EL Lipka, E Showalter, HDH Vincent, PW Elliott, WL Denny, WA

Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions, J MED CHEM, 43(7), 2000, pp. 1380-1397

Authors: Smaill, JB Rewcastle, GW Bridges, AJ Zhou, HR Showalter, HDH Fry, DW Nelson, JM Sherwood, V Elliott, WL Vincent, PW DeJohn, DE Loo, JA Greis, KD Chan, OH Reyner, EL Lipka, E Denny, WA

Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000), J MED CHEM, 43(16), 2000, pp. 3199-3199

Authors: Lipka, E Amidon, GL

Citation: E. Lipka et Gl. Amidon, Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems, J CONTR REL, 62(1-2), 1999, pp. 41-49

Authors: Axelrod, HR Kim, JS Longley, CB Lipka, E Amidon, GL Kakarla, R Hui, YW Weber, SJ Choe, S Sofia, MJ

Citation: Hr. Axelrod et al., Intestinal transport of gentamicin with a novel, glycosteroid drug transport agent, PHARM RES, 15(12), 1998, pp. 1876-1881